Axamon, pills 20mg, 50pcs

Composition

1 tablet contains:

Active ingredient:

ipidacrine hydrochloride monohydrate (Axamon) 20 mg (based on ipidacrine hydrochloride);

excipients:

ludipress (lactose monohydrate 93%, povidone 3.5%, crospovidone 3.5%) 65 mg,

sodium carboxymethyl starch 14 mg,

calcium stearate 1 mg

Pharmacological action

Pharmacodynamics .

Reversible cholinesterase inhibitor. Due to the blockade of potassium channels of cell membranes and inhibition of cholinesterase activity, it stimulates neuromuscular transmission and conduction of impulses in the nervous system.

It has M – and N-cholinomimetic effects. It enhances the effect of acetylcholine, serotonin, histamine and oxytocin on smooth muscles, as a result of which it increases the contractility of smooth muscle organs, including the gastrointestinal tract and bronchi, reduces heart rate, increases the secretion of salivary glands, contractile activity of the myometrium, and skeletal muscle tone.

It has a stimulating effect on the central nervous system in combination with individual manifestations of sedation; it helps to improve learning and memory.

Pharmacokinetics.

It is rapidly absorbed from the gastrointestinal tract. The maximum concentration in the blood plasma is reached after one hour.

40-55% of the Active ingredient binds to plasma proteins.

The elimination half-life is about 40 minutes. It is metabolized in the liver.

Excretion is carried out through the kidneys (mainly by tubular secretion and only 1/3 of the drug is excreted by glomerular filtration), as well as extrarenally (through the gastrointestinal tract).

Indications

• Diseases of the peripheral nervous system (neuritis, polyneuritis and polyneuropathy, polyradiculopathies, myasthenia gravis and myasthenic syndrome of various etiologies);
• Recovery period of organic lesions of the central nervous system, accompanied by motor disorders, including bulbar paralysis and paresis;
• Complex therapy of demyelinating diseases;
• Senile dementia, Alzheimer’s disease, encephalopathies of various origins.

Use during pregnancy and lactation

The use of the drug increases the tone of the uterus and can lead to premature birth, so ipidacrine is contraindicated during pregnancy.

There are no data on the use of the drug during breastfeeding.

Contraindications

Hypersensitivity to any of the components of the drug, epilepsy, extrapyramidal disorders with hyperkinesis, angina pectoris, severe bradycardia, bronchial asthma, mechanical obstruction of the intestine or urinary tract, vestibular disorders, gastric or duodenal ulcer in the acute stage, galactose intolerance, lactase deficiency or glucose-galactose malabsorption, pregnancy and lactation, children under 18 years of age.

Use caution when: gastric and duodenal ulcers in remission, thyrotoxicosis, disorders of intracardiac conduction; obstructive diseases of the respiratory system in the anamnesis or acute respiratory diseases.

Side effects

Caused by the excitation of m-cholinergic receptors: salivation, increased sweating, nausea, diarrhea, jaundice, bradycardia, epigastric pain, increased bronchial secretions, bronchospasm, convulsions, increased uterine tone.

Salivation and bradycardia can be reduced

with m-holinoblockers: atropine, trihexyphenidyl (cyclodol), metocinium iodide (metacin), etc.

Less frequently, after using higher doses, dizziness, ataxia, headache, vomiting, general weakness, drowsiness, skin reactions (pruritus, rash) were observed. In these cases, reduce the dose or stop taking the drug for a short time (for 1-2 days).

Interaction

Axamon ® enhances the sedative effect in combination with drugs that depress the central nervous system.

The effect and side effects are enhanced when combined with other cholinesterase inhibitors and m-cholinomimetic agents.

In patients with myasthenia gravis, the risk of developing a cholinergic crisis increases if Axamon® is used simultaneously with other cholinergic agents.

The risk of developing bradycardia increases if beta-blockers were used before starting treatment with Axamon®.

Weakens the inhibitory effect on the neuromuscular transmission and conduction of excitation along the peripheral nerves of local anesthetics, aminoglycosides, and potassium chloride.

Axamon® can be used in combination with nootropic drugs.

Alcohol increases the side effects of the drug.

How to take, course of use and dosage

Inside. The dose and duration of treatment are determined individually, depending on the severity of the disease.

Diseases of the peripheral nervous system, myasthenia gravis, myasthenic syndrome: 10-20 mg 1-3 times a day. The course of treatment is from one to two months. If necessary, the course of treatment can be repeated several times with a break between courses of 1-2 months.

Alzheimer’s disease, encephalopathy, recovery period of organic diseases of the central nervous system, accompanied by motor disorders, including bulbar paralysis and paresis: the daily dose is selected individually, usually 10-20 mg 2-3 times a day.

With demyelinating lesions of the nervous system, the dose can be increased to 20-40 mg 5-6 times a day. The maximum daily dose is 200 mg.

If one of the receptions was missed, then the usual dose of the drug is taken at the next reception.

Overdose

Symptoms: decreased appetite, bronchospasm, lacrimation, increased sweating, pupil constriction, nystagmus, increased gastrointestinal motility, spontaneous defecation and urination, vomiting, jaundice, bradycardia, impaired intracardiac conduction, arrhythmias, decreased blood pressure, anxiety, anxiety, agitation, fear, ataxia, convulsions, coma, speech disorders, drowsiness and general weakness.

Treatment: use of m-holinoblokatorov (atropine, cyclodol, metacin, etc. ), symptomatic therapy.

Special instructions

During treatment, you should refrain from driving a car, other vehicles and mechanisms, as well as from engaging in potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions.

Form of production

Pills.

Storage conditions

Store in a dry place, protected from light, at a temperature not exceeding 25 °C

Shelf life

3 years

Active ingredient

Ipidacrine

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For adults as directed by your doctor

Indications

Alzheimer’s Disease, Stroke Effects, Polyneuropathy